New Antiretroviral Treatment for HIV

被引：11

作者：

Badowski M.E. ^{[1
]}

Pérez S.E. ^{[2
]}

Biagi M. ^{[3
]}

Littler J.A. ^{[4
]}

机构：

[1] Sections of Infectious Diseases Pharmacotherapy and Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, IL

[2] Department of Pharmacy, Tufts Medical Center, Boston, MA

[3] Franciscan St. Margaret’s Health Hammond, Hammond, IN

[4] St. Mary and St. Elizabeth Medical Center, Chicago, IL

来源：

Infectious Diseases and Therapy | 2016年 / 5卷 / 3期

关键词：

Antiretrovirals; HIV pipeline; HIV/AIDS; HIV/AIDS treatment;

D O I：

10.1007/s40121-016-0126-x

中图分类号：

学科分类号：

摘要：

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set the global goal of ending the AIDS world epidemic by 2030. In order to end this epidemic they have established a 90-90-90 goal to be achieved by 2020, which may be problematic, especially in low- and middle-income countries. This goal includes 90% of individuals with HIV globally being diagnosed, on treatment, and virologically suppressed. Based on global estimates from 2014–2015, approximately 36.9 million individuals are living with HIV. Of those, 53% have been diagnosed with HIV, 41% are on antiretroviral therapy (ART), and 32% have viral suppression with <1000 copies/ml. Comprehensive approaches are needed to improve the number of people living with HIV (PLWH) who are diagnosed, linked, and engaged in care. Once PLWH are retained in care, treatment is key to both HIV prevention and transmission. The development and advancement of new ART is necessary to assist in reaching these goals by improving safety profiles, decreasing pill burden, improving quality of life and life expectancy, and creating new mechanisms to overcome resistance. The focus of this review is to highlight and review data for antiretroviral agents recently added to the market as well as discuss agents in various stages of development (new formulations and mechanisms of action). © 2016, The Author(s).

引用

页码：329 / 352

页数：23

共 60 条

[1]

Levi J., Raymond A., Pozniak A., Can the UNAIDS 90-90-90 target be reached? Analysis of 12 national level HIV treatment cascades. Abstract MOAD0102, International AIDS Society, Vancouver, Canada, Jul, pp. 19-22, (2015)

[2]

INSIGHT START Study Group, Initiation of antiretroviral therapy in early asymptomatic HIV infection, N Engl J Med, 373, pp. 795-807, (2015)

[3]

A trial of early antiretrovirals and isoniazid preventive therapy in Africa, N Engl J Med, 373, pp. 808-822, (2015)

[4]

Cohen M.S., Chen Y.Q., McCauley M., Et al., Prevention of HIV-1 infection with early antiretroviral therapy, N Engl J Med, 365, pp. 493-505, (2011)

[5]

Grant R.M., Lama J.R., Anderson P.L., Et al., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men, N Engl J Med, 363, pp. 2587-2599, (2010)

[6]

Ryom L., Boesecke C., Gisler V., Et al., Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons, HIV Med, 17, pp. 83-88, (2016)

[7]

Raffi F., Jaeger H., Quiros-Roldan E., Et al., Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 13, pp. 927-935, (2013)

[8]

Clotet B., Feinberg J., van Lunzen J., Et al., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet, 383, pp. 2222-2231, (2014)

[9]

Molina J.-M., Clotet B., van Lunzen J., Dolutegravir is superior to darunavir/ritonavir in treatment-naive HIV-1 infected individuals: 96 week results from FLAMINGO. Slides O153. Presented at: HIV Drug Therapy Glasgow

[10]

November 2–6, (2014)

← 1 2 3 4 5 6 →